Form 4 for VRDN Viridian Therapeutics, Inc.\DE
Accepted 2022-11-16 00:00:00 ET · period of report 2022-11-15 · accession 0000899243-22-036044 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-11-16 | 2022-11-15 | VRDN | Meisner Lara | GC, Sec | S - Sale+OE | $22.05 | -8,125 | 0 | -100% | -$179.2K |
| D | 2022-11-16 | 2022-11-15 | VRDN | Meisner Lara | GC, Sec | M - OptEx | $14.00 | +8,125 | 8,125 | New | +$113.8K |
| D | 2022-11-16 | 2022-11-15 | VRDN | Meisner Lara | GC, Sec | M - OptEx | $0.00 | -8,125 | 21.9K | -27% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-11-15 | S | D | 8,125 | $22.05 | 0 | D | — | — | (F1) This transaction was executed pursuant to a Rule 10b5-1 trading plan in multiple trades at prices ranging from $21.04 to $22.845. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected. |
| 2 | Common | Common Stock | 2022-11-15 | M | A | 8,125 | $14.00 | 8,125 | D | — | — | |
| 3 | Derivative | Stock Option (Right to Buy) | 2022-11-15 | M | D | 8,125 | $0.00 | 21,875 | D | $14.00 · — to 2031-09-22 | 8,125 Common Stock | (F2) The option vested 25% on September 22, 2022 and the remainder vests in equal monthly installments over the following 3 years, subject to the Reporting Person's continued service to Issuer through each vesting date. |